APA (7th ed.) Citation

CW, C., RM, R., A, V. L., EM, F., OS, K., GS, L., . . . PS, L. (2022). Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology, 99(6), 260. https://doi.org/10.1212/WNL.0000000000201005

Chicago Style (17th ed.) Citation

CW, Christine, Richardson RM, Van Laar A, Fine EM, Khwaja OS, Liang GS, Bankiewicz K, and Larson PS. "Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial." Neurology 99, no. 6 (2022): 260. https://doi.org/10.1212/WNL.0000000000201005.

MLA (9th ed.) Citation

CW, Christine, et al. "Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial." Neurology, vol. 99, no. 6, 2022, p. 260, https://doi.org/10.1212/WNL.0000000000201005.